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Abstract
Objective—White matter hyperintensities (WMH) detectable by magnetic resonance imaging
(MRI)are part of the spectrum of vascular injury associated with aging of the brain and are thought
to reflect ischemic damage to the small deep cerebral vessels. WMH are associated with an
increased risk of cognitive and motor dysfunction, dementia, depression, and stroke. Despite a
significant heritability, few genetic loci influencing WMH burden have been identified.
Methods—We performed a meta-analysis of genome-wide association studies (GWAS) for
WMH burden in 9,361 stroke-free individuals of European descent from 7 community-based
cohorts. Significant findings were tested for replication in 3,024 individuals from 2 additional
cohorts.
Results—We identified 6 novel risk-associated single nucleotide polymorphisms (SNPs)in one
locus on chromosome 17q25 encompassing 6 known genes including WBP2, TRIM65, TRIM47,
MRPL38, FBF1, and ACOX1. The most significant association was for rs3744028 (Pdiscovery=
4.0×10−9; Preplication =1.3×10−7; Pcombined =4.0×10−15). Other SNPs in this region also reaching
genome-wide significance are rs9894383 (P=5.3×10−9), rs11869977 (P=5.7×10−9), rs936393
(P=6.8×10−9), rs3744017 (P=7.3×10−9), and rs1055129 (P=4.1×10−8). Variant alleles at these loci
conferred a small increase in WMH burden (4–8% of the overall mean WMH burden in the
sample).
Interpretation—This large GWAS of WMH burden in community-based cohorts of individuals
of European descent identifies a novel locus on chromosome 17. Further characterization of this
locus may provide novel insights into the pathogenesis of cerebral WMH.
INTRODUCTION
The burden of vascular injury to the aging brain is far greater than that of clinically-manifest
neurological conditions, such as stroke and dementia, and the harmful effects of brain
vascular disease begin well before clinical symptoms become apparent.1 Abnormalities of
the white matter of the brain are readily identified on magnetic resonance imaging (MRI) as
areas of signal hyperintensity on T2-weighted and fluid-attenuated inversion-recovery
sequences. White matter hyperintensities(WMH), also known as leukoaraiosis, are
remarkably common in healthy individuals beginning in middle age, with prevalence
ranging from 40–70% in the fifth decade of age.2 They contribute a substantial public health
burden since they are associated with an increased risk of cognitive deficits, motor function
impairment, dementia, depression, and stroke. The pathophysiology of WMH is poorly
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understood but may reflect ischemic damage to the small deep vessels of the brain resulting
from arteriolosclerosis and leading to myelin degeneration or rarefaction, proliferative
astrogliosis, fibrinoid changes and fibrosis of the vessel wall.3 In addition to age, elevated
blood pressure is a major risk factor for WMH. Genetic factors appear also to play a
significant role, with a heritability ranging from 55% to 80%.4–6 Yet, studies conducted to
date offer few specific clues about these genetic factors.7–9 Genome-wide association
studies (GWAS) provide a powerful tool for identifying genes related to complex traits.10
We have conducted a meta-analysis of GWAS data for WMH burden in 9,361 individuals of
European descent (mean age 69.5 years; 42.6% men) and belonging to 7 community-based
cohort studies: the Aging Gene-Environment Susceptibility-Reykjavik Study (AGES-
Reykjavik); the Atherosclerosis Risk in Communities (ARIC) Study; the Austrian Stroke
Prevention Study (ASPS); the Cardiovascular Health Study (CHS); the Framingham Heart
Study (FHS); and two cohorts from the Rotterdam Study (RS). The participating studies
were prospective population-based cohort studies with available cerebral MRI and genome-
wide genotyping data and collaborating in the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) Consortium.11
SUBJECTS AND METHODS
Consortium organization and study sample
The CHARGE consortium is an investigator-initiated collaboration to facilitate GWAS
meta-analyses among multiple large and well-phenotyped cohort studies.11 All participating
studies worked cooperatively to address issues related to phenotype harmonization,
covariate selection and to develop analytic plans for within-study GWAS analyses and meta-
analysis of results. Each study received institutional review board approval of its consent
procedures, cohort’s examination and surveillance, DNA collection and use, and data access
and distribution. All participants in this study gave written informed consent for study
participation, MRI scanning, and use of DNA.
Details of cohort recruitment, risk factor assessment, phenotyping and genotyping are
described in the Supplementary Material. Briefly, in all cohorts, participants were excluded
if they lacked information on MRI, genotypes, or both, or if they suffered a stroke or
transient ischemic attack prior to MRI. In addition, CHS did not genotype participants with
clinical cardiovascular disease at baseline. The ASPS and Rotterdam Study did not perform
MRI scans in participants with dementia, and FHS analyses excluded participants who had
dementia at the time of MRI scanning. Table 1 shows the number and characteristics of
participants from each cohort.
MRI scans
In each study, MRI scans were performed and interpreted in a standardized fashion, without
reference to demographic or clinical information. The field strength of the scanners used
ranged from 0.5T to 1.5 Tesla. T1-and T2-weighted scans in the axial plane were obtained
for all participants. These were complemented by either scans obtained with fluid
attenuation inversion recovery or proton density sequences to allow better separation of
white matter hyperintensities and cerebrospinal fluid. In AGES-Reykjavik, ASPS, FHS, and
RS, WMH volume was estimated on a quantitative scale using custom-written computer
programs based on an automatic segmentation algorithm or a semi-automatic segmentation
analysis involving operator-guided removal of non-brain elements. In ARIC and CHS,
WMH volume was estimated on a semi-quantitative 10-point scale by visual comparison
with eight templates that successively increased from barely detectable white matter lesions
to extensive, confluent abnormalities. Study participant’s brain images were compared with
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the reference standards after aligning them to approximately the same apparent size. Hence,
visual grades are inherently normalized for brain size.
Comparability between the volumetric and visual scales was carefully evaluated. The
distribution of WMH scores and the standardized slopes of associations between WMH
scores and age were examined in each cohort and shown to be similar across the cohorts.
Direct comparison of volumetric segmentation to visual scoring was performed using WMH
measurements obtained by both methods in 1134 ARIC participants and showed a very good
overall agreement (R2>0.80)(Supplementary Material).12 In addition, volumetric analysis of
the visual scoring standard image sets was conducted and showed excellent agreement on
the log scale (R2=0.98) (Shibata, personal communication).
Genotyping
The participating studies used different genotyping platforms. Thus, genotype data in each
study was used to impute to the 2.5 million non-monomorphic, autosomal SNPs described in
the HapMap’s CEU panel. Extensive quality control (QC) analyses were performed in each
cohort(Supplementary Material). Briefly, participant-specific quality controls filters were
applied based on missing call rate, cryptic relatedness, and number of Mendelian errors per
individual. SNP-specific quality controls included filters for call rate, minor allele
frequency, Hardy-Weinberg equilibrium, differential missingness by outcome or genotype,
and imputation quality.
Statistical analyses and meta-analysis
Within each study, a linear regression model was used to evaluate the association of the
natural log-transformed volume of WMH(log(WMH+1)) with the number minor allele (0 to
2) at each SNP. Analyses were adjusted only for age, sex, and total intra-cranial volume
(except in ASPS, ARIC and CHS). ARIC and CHS also adjusted for study site, and FHS
adjusted for familial structure. The most significant association analyses were further
adjusted for systolic blood pressure or for hypertension. All studies screened for latent
population substructure, which was negligible(Supplementary Material).
A fixed-effects meta-analysis of results from the seven discovery cohorts was conducted
using a z-score based method, as justified in the Supplementary Material. This approach is
appropriate given that WMH was measured on different scales (mlor unit-less grade) in the
various cohorts. The genomic control parameter was calculated and used to remove any
residual population stratification within cohort and in the combined meta-analysis.13 We
used a genome-wide significance threshold of 5×10−8. This threshold was first proposed
based on the testing of 1 million SNPs and uses the simple Bonferroni correction for
multiple tests.14 It is widely used in GWAS studies and is similar to genome-wide
significance thresholds estimated by more complex methodologies.15
Replication and extension
Replication was sought for SNPs reaching genome-wide significance. The first replication
sample comprised 1607 white participants (mean age 76.4±5.6) from the AGES-Reykjavik
study who had not undergone genome-wide genotyping and, thus, were not part of the
discovery sample. The second comprised 1417 white elderly non-institutionalized
participants in the 3C-Dijon study (mean age 72.3±4.1). Association analyses in the
replication cohorts used the same statistical models as those in the discovery cohorts.
Results of the association of the genome-wide significant SNPs with WMH burden in the
two replication cohorts were combined by meta-analysis using an inverse-variance weighted
method. Significance and extent of heterogeneity were evaluated using the Cochran Q and I2
statistics.16
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We also sought to explore the association of SNPs in chromosome 17q25 region with WMH
burden in 807 African-Americans from the ARIC study (mean age 61.5±4.5)with MRI and
genotype data. Details on these groups are provided in the Supplementary Material.
RESULTS
There was no evidence of genomic control factor inflation within each cohort analyses and
in the meta-analysis (λ=1.02) (Supplementary Material). Figure 1 shows the genome-wide
plot of P-values for the individual SNPs against their genomic position. Six SNPs reached
the genome-wide significance threshold of P<5×10−8, and an additional 56SNPs showed
associations with P<1×10−5. They belonged to 15 loci (r2<0.5 between loci) (Table 2). At a
threshold of P<1×10−4, a total of 416 SNPs were associated with WMH burden
(Supplementary Table 1).
The most significant association was identified for rs3744028 at position 71400267
(Genome Build 36) on chromosome 17q25. In all studies, the C allele (frequency = 0.18)
was significantly associated with a greater WMH burden (P=4.0×10−9). This SNP belonged
to a larger cluster of associated SNPs spanning a 108 kb region (Figure 2). The other SNPs
in this region also reaching genome-wide significance are rs9894383 (P=5.3×10−9),
rs11869977 (P=5.7×10−9), rs936393 (P=6.8×10−9), rs3744017 (P=7.3×10−9), and
rs1055129 (P=4.1×10−8). The first four were in strong linkage disequilibrium (LD) with
rs3744028 and with each other (r2>0.8). The fifth (rs1055129) was in moderate LD with
rs3744028 (r2=0.5). rs3744028 is located in intron 2 of the tripartite motif-containing 65
gene (TRIM65); rs1055129 and rs3744017 are located in introns 1 and 5, respectively, of the
TRIM47 gene; rs936393 is located in intron 2 of the WW domain binding protein 2 gene
(WBP2); and rs9894383 and rs11869977 are located in the region between the TRIM47 and
WBP2 genes. After adjustment for systolic blood pressure, the significance of the
association was P=1.5×10−9 for rs3744028 and P=1.2×10−8 for rs1055129. Similarly, after
adjustment for hypertension, the significance of the association was P=1.0×10−9 for
rs3744028 and P=1.1×10−8 for rs1055129.
The next most significantly associated locus(although not reaching genome-wide
significance)was identified on chromosome 10q24 in a region that partially overlaps with a
region recently identified to influence systolic blood pressure in two genome-wide
association studies of whites.17, 18 Four SNPs showed highly suggestive associations, with
the most significant SNP, rs7894407 (P=6.1×10−7), located in intron 12 of the programmed
cell death 11 gene (PDCD11).
In addition to the two above loci, three additional SNPs with P<1×10−5 were located within
known coding genes, including the polyamine-modulated factor 1 gene (PMF1), the
collagen type XXV alpha 1 gene (COL25A1), and the methylenetetrahydrofolate
dehydrogenase 1 gene (MTHFD1)(Table 2).
Association of rs3744028 and rs1055129 with WMH burden was replicated in an
independent sample of 1607 AGES-Reykjavik participants. The C allele of rs3744028 and
the G allele of rs1055129 were significantly associated with a greater WMH burden
(P=1.3×10−5 and 4.7×10−4, respectively). Adjustment for systolic blood pressure or
hypertension did not substantially change these results (rs3744028, P=2.2×10−5 and
1.3×10−5, respectively; rs1055129, P=7.1×10−4 and 6.0×10−4, respectively).
Association of these 2 SNPs was also investigated in 1417 elderly white participants from
the 3C-Dijon study. The C allele of rs3744028 was significantly associated with a greater
WMH burden (P=0.002). However, no association of rs1055129 with WMH burden was
observed (P=0.11). Adjustment for systolic blood pressure or hypertension did not
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substantially change these results (rs3744028, P=0.001 and 0.001, respectively; rs1055129,
P=0.11 and 0.09, respectively).
A summary meta-analysis of the 2 SNP association results in the replication cohorts and in
all cohorts combined are shown in Table 3. In the replication cohorts, significance of the
association of rs3744028 and rs1055129 with WMH burden was 2.0×10−7 and 5.9×10−4,
respectively. The associated risk alleles increased WMH burden by a quantity of 0.12 and
0.07, respectively, on the transformed log-scale, with WMH expressed in ml. This is
equivalent to an increase of 8.3% and 4.8%, respectively, of the overall mean WMH
burden(expressed in the same scale) in this sample. In the combined sample of 12,385
individuals of European descent, the significance of the association of rs3744028 and
rs1055129 reached P=4.0×10−15 and 2.6×10−11, respectively. The direction of effects was
generally consistent across the studies and there was no evidence of between-study
heterogeneity within the replication cohorts (Table 3).
We also investigated the association of SNPs in the chromosome 17q25 region with WMH
burden in 807 African-Americans from the ARIC cohort. Allele frequencies were 0.23, 0.13,
for rs3744028 and rs1055129, respectively. None of the top SNPs identified in whites was
associated with WMH burden in this sample of African-Americans (P=0.66, rs3744028;
P=0.91, rs1055129). However, assuming the same effects sizes as those observed in the
white replication cohorts, power to detect an association was 57% for rs3744028 and 13%
for rs1055129 in this small sample of African Americans. Because the pattern of LD in these
regions differs between populations of European and African descent (Supplementary
Figure 3), we examined the association of 7 additional genotyped SNPs located within a
50kb distance of the top SNPs on chromosome 17, respectively. None of the 7 SNPs on
chromosome 17q25 was associated with WMH burden(Supplementary Table 2). The lowest
P-value was obtained for rs6501841 within the Fas-binding factor 1 (FBF1) gene (P=0.11).
A search for putative functional SNPs among our highly suggestive association results
identified 4 non-synonymous coding variants and 2 SNPs located in splice sites
(Supplementary Material). Five of the six putative functional SNPs were located on
chromosome 17q25. rs2290771 (P=4×10−7) in a splice site of the WBP2 gene and
rs3760128 (P=8×10−7) encoding a leucine to proline substitution in TRIM65 were in
moderate to high LD with one another and with rs1055129 (r2=0.7). We also screened SNPs
tagging the chromosome 17q25 locus against a set of previously reported expression-
associated SNPs (eSNPs). Six SNPs, in moderate to strong LD with rs3744028 or
rs1055129, were significantly associated with variation in exon-level expression of FBF1 in
cortical brain tissue.19 Seven SNPs, including rs3744028, were associated with variation in
mRNA expression levels of TRIM47 in lymphoblastoid cell lines.20, 21
We also examined whether the 2 SNPs on chromosome 17q25 were associated with incident
ischemic stroke, incident dementia, and Alzheimer’s disease (AD) using pre-computed
results from genome-wide association meta-analyses of these endpoints in the CHARGE
cohorts.22, 23 Neither rs3744028 nor rs1055129 was associated with risk of incident
ischemic stroke, dementia, or AD (Supplementary Table 3).
A systematic review of published candidate gene association studies identified a limited
number of polymorphisms most frequently investigated for their association with WMH.8
Data were available for 15 of the 20 candidate SNP spreviously reported associated with
WMH. Two SNPs reached the nominal level of significance of P<0.05 (rs5498 (K469E) in
the intercellular adhesion molecule 1 gene (P=0.006) and rs699 (M235T) in the
angiotensinogen gene (P=0.01)) but these associations were not significant after correction
for multiple tests (Supplementary Material and Supplementary Table 4).
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In this meta-analysis of genome-wide association data from 9,361 individuals of European
descent, we identified novel genetic associations with WMH burden. Six SNPs mapping to a
locus on chromosome 17q25 reached genome-wide significance, of which five were in
strong LD. We replicated associations of two of these SNPs – rs3744028 and rs1055129 – in
an additional 3,024 individuals of European descent. In a meta-analysis combining data
from all 12,385 individuals, both showed strong associations with variation in WMH burden
(rs3744028, P=4.0×10−15; rs1055129, P=2.6×10−11). These SNPs belong to a large cluster
of associated SNPs spanning a ~100 kb region, which contains several genes: Two tripartite
motif-containing genes, TRIM65 and TRIM47; the WW domain binding protein 2 gene
(WBP2); the mitochondrial ribosomal protein L38 gene (MRPL38); the Fas-binding factor 1
gene (FBF1); the acyl-coenzyme A oxidase 1 gene (ACOX1), and the C-Elegans homolog
UNC13D gene. TRIM65 and TRIM47 are members of a superfamily of ring-finger B-box
coiled-coil (RBCC) proteins involved in a broad range of biological processes including
innate immunity 24, apoptosis, cell cycle regulation, vesicular trafficking, and
neuroprotection.25 TRIM47 was first identified as over-expressed in astrocytomas.26 WBP2
encodes a protein that was shown to interact with the WW domain of the Yes kinase-
associated protein (YAP) and may play an important role in transcription regulation.27 FBF1
was identified in a yeast two-hybrid assay to interact with the Fas cell surface receptor, a
member of the TNF-receptor superfamily and a key regulator of apoptosis.
Histopathological studies have shown evidence of apoptosis in white matter lesions.28
Moreover, apoptosis-related transcripts have been shown to be differentially expressed
between white matter lesions and normal white matter of brains collected postmortem from
donors.29 ACOX1 is the first enzyme of the fatty acid beta-oxidation pathway. Similar to
other defects in peroxisomal beta-oxidation, ACOX1 deficiency is a rare disorder
characterized by severe white matter abnormalities. Mutations in the UNC13D gene have
been implicated in familial hemophagocytic lymphohistiocytosis, a rare disorder
characterized by an uncontrolled proliferation and infiltration of activated lymphocytes and
macrophages and an overproduction of inflammatory cytokines. Abnormalities of the brain
white matter have been documented in this disorder.30 The two SNPs identified in this
genome-wide association study have been associated with variation in FBF1 expression in
the brain and TRIM47 in lymphoblastoid cell lines.21, 31 In addition, they were in moderate
to high LD with several putative functional polymorphisms in TRIM65 and WBP2, raising
the possibility that multiple genes may be at play in the relationship between sequence
variation at the 17q25 locus and WMH burden.
This prospective meta-analysis of GWAS data for WMH volume included a large sample
size of individuals of European descent with high-quality genotypic and MRI data. In this
study, white matter disease burden was defined as a continuous variable rather than a
dichotomized one (presence/absence). Indeed, white matter disease burden is continuously-
distributed and graded in the population and analysis of the continuous trait generally yields
greater power to detect genetic effects.
Despite these clear strengths, some limitations of the study must be acknowledged. WMH
measures were obtained on different scales in the studies. Although there is very good
agreement between the visual and volumetric scales known differences in sensitivity,
specificity, and precision between the semi-quantitative and quantitative methods have
likely reduced our power to detect genetic effects. Effect sizes of the two SNPs on
chromosome 17q25 estimated from a meta-analysis of the replication results showed that
each of the identified risk alleles was associated with a small increase in WMH burden (4–
8% of the overall mean WMH burden in this sample). Our analyses considered burden of
WMH over the whole brain and did not address possible regional differences in the
Fornage et al. Page 7













distribution of WMH. In particular, periventricular and subcortical WMH are thought to
have different pathophysiology, risk factors, and functional consequences.32 However, the
significant genetic correlation between these two forms of white matter disease suggests that
they are influenced at least in part by common genetic factors.33 While this GWAS analysis
conducted in whites of European descent has the advantage of minimizing potential
population stratification issues, our findings may not necessarily be generalized to other
ethnic groups. Indeed, we did not find any evidence of an association of SNPs at 17q25 with
WMH burden in African-Americans. The lack of extension to African-Americans should be
interpreted cautiously as our small sample lacked power to detect associations of similar
effect size as those observed in whites. In addition, reduced genomic coverage of the
chromosome 17q25 locus in African-American may also explain the lack of significant
findings in this population. Finally, we can also not exclude the possibility that genetic
factors influencing WMH burden may not fully overlap between African-Americans and
Whites. Linkage studies performed in various ethnic groups have also failed to identify
common chromosomal regions influencing WMH.9, 33 Additional GWAS for WMH burden
in African-Americans or other ethnic groups are needed.
Fine-mapping of the WMH locus on chromosome 17q25 was not attempted in this study.
Hence, information on the specific genes and functional variant(s) underlying the reported
associations is lacking. Neither of the two WMH SNPs was associated with risk of incident
ischemic stroke, dementia, or late-onset AD in previously conducted GWAS analyses of
these outcomes in the CHARGE cohorts.22, 23 This is perhaps not surprising in light of the
small effect size of these SNPs on WMH burden and the complex relationships between
white matter injury and its clinical expression. Indeed, it is generally believed that
endophenotypes may be closer, in the biological hierarchy, to the genetic underpinnings than
clinical disease outcomes, and thus, the impact of genetic variation on these endophenotypes
is expected to be greater. The effects of the identified SNPs on WMH burden are small and
likely even smaller on the clinical endpoints. Hence, our power to detect such effects was
limited and studies adequately addressing the association of the WMH SNPs with these
outcomes will require very large cohorts or clinical samples. The trend toward a protective
effect of the 2 SNPs on incident ischemic stroke should be interpreted with caution: First,
the association analyses were underpowered and likely resulted in imprecise effect
estimates. Second, the samples used in the meta-analyses of WMH and clinical endpoints
GWAS data were not identical and difference in LD between samples could lead to
inconsistent patterns of associations when non-causal variants are tested.34 Finally,
association of the WMH SNPs with clinical endpoints may be influenced by unrecognized
(and unaccounted) factors such as other genetic loci or environmental variables, and such
interactions may complicate interpretation of the association results.
In summary, this large GWAS of WMH burden in community-based cohorts of individuals
of European descent has identified a novel locus on chromosome 17q25 and provides a first
step towards characterization of the biological mechanisms that influence the
pathophysiology associated with WMH burden, an important risk factor of stroke, cognitive
impairment and dementia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Genome-wide association results of WMH burden. Meta-analysis P-values are plotted
against their genomic position. The horizontal line indicates the threshold for genome-wide
significance.
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Regional association plot centered around rs3744028. Meta-analysis P-values for SNPs
located within a 200 kb region on chromosome 17q25 are plotted against their genomic
position.
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